About Carboxypeptidase A2
Carboxypeptidase A2 (CPA2) is a protein
from Homo sapiens identified by UniProt accession
P48052, 419 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Carboxypeptidase A2 |
| UniProt accession | P48052 |
| Gene | CPA2 |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (69)
Diseases linked to this target (Open Targets).
- drug use measurement · score 0.08
- Female infertility due to fertilization defect · score 0.06
- hereditary hyperferritinemia with congenital cataracts · score 0.05
- femoral hernia · score 0.05
- blood protein measurement · score 0.05
- gastric carcinoma · score 0.05
- Cataract-microcornea syndrome · score 0.05
- female infertility due to oocyte meiotic arrest · score 0.05
- Hydatidiform Mole · score 0.04
- premature ovarian failure 19 · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P48052-F1 | alphafold | PREDICTED | 95.04 | — |
Amino-acid sequence (419 residues)
MAMRLILFFG ALFGHIYCLE TFVGDQVLEI VPSNEEQIKN LLQLEAQEHL QLDFWKSPTT PGETAHVRVP FVNVQAVKVF LESQGIAYSI MIEDVQVLLD KENEEMLFNR RRERSGNFNF GAYHTLEEIS QEMDNLVAEH PGLVSKVNIG SSFENRPMNV LKFSTGGDKP AIWLDAGIHA REWVTQATAL WTANKIVSDY GKDPSITSIL DALDIFLLPV TNPDGYVFSQ TKNRMWRKTR SKVSGSLCVG VDPNRNWDAG FGGPGASSNP CSDSYHGPSA NSEVEVKSIV DFIKSHGKVK AFITLHSYSQ LLMFPYGYKC TKLDDFDELS EVAQKAAQSL RSLHGTKYKV GPICSVIYQA SGGSIDWSYD YGIKYSFAFE LRDTGRYGFL LPARQILPTA EETWLGLKAI MEHVRDHPY
Explore Carboxypeptidase A2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets